 |
 |
Scroll down to Andy's message, folks... -----Original Message----- From: Andy Blatz <[log in to unmask]> To: [log in to unmask] <[log in to unmask]> Date: Friday, October 23, 1998 4:44 PM Subject: FW: Aspirin protects against MPTP in mice >Dear Ms. Mallut, > >My company cheerfully changed our email address which prevents me from >posting to subscribed lists until I resubscribe. In the meantime, would >you mind posting the following (if someone doesn't get it up before)? It >is kind of interesting, although the dose of aspirin that they use is HUGE >and probably not tolerable in people. > >Thanks, >Andy >---------- >From: Andy Blatz >Sent: Friday, October 23, 1998 5:22 PM >To: [log in to unmask] >Subject: FW: Aspirin protects against MPTP in mice > > > >---------- >From: WE MOVE [SMTP:[log in to unmask]] >Sent: Friday, October 23, 1998 3:48 PM >To: [log in to unmask] >Subject: Aspirin protects against MPTP in mice > >Aspirin and salicylate protect against MPTP-induced dopamine depletion >in mice >Aubin N, Curet O, Deffois A, Carter C. >J Neurochem.1998;71(4):1635-1642 > >Aspirin and salicylate can prevent MPTP-induced dopamine depletion in mice, >according to this study. The protective effect extends for at least two >weeks after MPTP administration. >Aspirin and salicylate were administered intraperitoneally in doses up to >100 mg/kg, at times ranging from 2 hours before to 6 hours after MPTP >administration. Levels of striatal dopamine and a variety of metabolites >were quantified with HPLC and electrochemical detection. >MPTP-induced DA depletion was blocked in a dose-dependent and >time-dependent manner by both aspirin and salicylate. Maximal protection of >aspirin occurred with a dose of 100 mg/kg administered within one hour on >either side of MPTP injection. Striatal DA levels remained normal for at >least 2 weeks following MPTP/salicylate challenge. >The authors do not propose a specific protective mechanism, but rule out >several candidates, including: >. cyclooxygenase inhibition, since none of several other COX inhibitors >exhibited similar effects >. effects on DA uptake, MAO-B activity, MPTP metabolism, or MPT+ uptake, >since no effect was seen on these >. hypothermia >. NF-kB inhibition, since dexamethasone had no protective effect >. NOS inhibition, since salicylate has no effect on NOS activity > >They did find an increase in hydroxylated salicylate, suggesting the >possibility of a free radical scavenging effect. >The authors conclude, "It is...surprising and exciting that these two drugs >are able to prevent completely neurotoxic effects in this animal model of >Parkinson's disease-an observation that merits close clinical attention." > >-- >Copyright 1998 WE MOVE >Editor: Richard Robinson ([log in to unmask]) >E-MOVE archives, plus information on subscribing and unsubscribing, are >available at http://www.wemove.org/em_intro.html > >E-MOVE is a service of WE MOVE (Worldwide Education and Awareness for >Movement Disorders) >204 West 84th Street >New York, NY 10024 > >TEL 800-437-MOV2 >TEL 212-241-8567 >FAX 212-987-7363 >http://www.wemove.org > >